V5med AI Lung Diagnostic Platform
AI-powered LDCT platform for lung nodules, emphysema, fibrosis, and coronary calcification detection
Software · On PremiseCompany source
Company profile
About V5med
V5med Inc. is a medical imaging AI company specializing in lung and cardiac diagnostics through advanced computer vision and deep learning. The company is the first AI-based lung diagnostic software company in Taiwan to receive U.S. FDA 510(k) clearance. V5med's platform leverages low-dose CT (LDCT) imaging and AI algorithms to support early detection and quantification of lung nodules, emphysema, pulmonary fibrosis, and coronary artery calcification in a single scan. Built on over a decade of expertise in high-speed imaging, deep learning, and computer vision, V5med's solutions are clinically validated to increase nodule detection sensitivity by over 95%, with up to 20% improvement in radiologist accuracy. The system is Lung-RADS compatible and optimized for detecting ground-glass nodules (GGNs), making it ideal for lung cancer screening programs and routine chest CT workflows. V5med is backed by V5 Technologies, a global leader in optical metrology and semiconductor inspection systems, bringing deep engineering and image analysis expertise into healthcare AI. The company's solutions are PACS-integrated, vendor-neutral, and scalable across radiology networks and screening centers. V5med has deployed its solutions across hospitals in Taiwan, Japan, Vietnam, Thailand, and Indonesia, and is expanding into North America.
Company description V5med official website
Primary marketMedical Imaging & Radiology
Commercial modelCommercial information available on request
Company presenceOfficial website
Work at V5med?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Coronary artery calcification
- Emphysema
- Ground-glass nodules (GGNs)
- Lung cancer
- Lung nodules
- Pulmonary fibrosis
Who it serves
- Hospitals
- Radiology networks
- Screening centers
Deployment & integration
On Premise deployment with recorded integration context.
Recorded integration context: PACS.
Geographic context
MarketsIndonesia · Japan · North America (expanding) · Taiwan · Thailand · Vietnam
Company sourceOfficial website
Company milestones
Platform expansion
Received U.S. FDA 510(k) clearance in March 2025, becoming Taiwan's first AI lung diagnostic software company with FDA clearance. Obtained Taiwan TFDA certification in late 2022. Expanding into North American market.
Partnerships
Recorded partners
- Multiple hospitals in Taiwan, Japan, Vietnam, Thailand, and Indonesia
- V5 Technologies (parent company)
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Enhanced labor pain monitoring using machine learning and ECG waveform analysis for uterine contraction-induced pain.BioData mining · Sep 7, 2024
Clinical validation
Clinical-trial records
Retrospective Validation of AccuPulmo CT Portal for Detecting Pulmonary Fibrosis on Chest CTNCT07761377 · Sponsor · RECRUITING
Regulatory
Regulatory records
V5med Lung AIK242919 · 510k · Mar 27, 2025
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
Nodule detection sensitivity over 95%
Clinical validation studies
Up to 20% improvement in radiologist accuracy
Clinical validation studies
Hospitals in Taiwan, Japan, Vietnam, Thailand, and Indonesia
Deployment of AI-powered lung diagnostic platform for early detection of lung nodules, emphysema, pulmonary fibrosis, and coronary artery calcification
Over 95% nodule detection sensitivity with up to 20% improvement in radiologist accuracy
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from V5med
Recent articles published on V5med's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.